An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

558

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Asthma
Interventions
DRUG

Budesonide/formoterol (SYMBICORT) pMDI

SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily

DRUG

Budesonide HFA pMDI

Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily

Trial Locations (39)

Unknown

Research Site, Anaheim

Research Site, Chula Vista

Research Site, Fresno

Research Site, Fullerton

Research Site, Los Angeles

Research Site, National City

Research Site, Rancho Cordova

Research Site, Rancho Mirage

Research Site, Riverside

Research Site, Sacramento

Research Site, San Diego

Research Site, San Francisco

Research Site, Stockton

Research Site, Torrance

Research Site, Pueblo

Research Site, Largo

Research Site, Miami

Research Site, Naranja

Research Site, North Miami

Research Site, Orlando

Research Site, Panama City

Research Site, South Miami

Research Site, Chicago

Research Site, Newburgh

Research Site, Oklahoma City

Research Site, Philadelphia

Research Site, Boerne

Research Site, El Paso

Research Site, Fort Worth

Research Site, Houston

Research Site, San Antonio

Research Site, Spring

Research Site, Aguas Buenas

Research Site, Caquas

Research Site, Cidra

Research Site, Levittown

Research Site, Ponce

Research Site, SanJuan

Research Site, Trujillo Alto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY